4.5 Article

Prostate Cancer, Version 1.2016 Featured Updates to the NCCN Guidelines

Journal

Publisher

HARBORSIDE PRESS
DOI: 10.6004/jnccn.2016.0004

Keywords

-

Categories

Funding

  1. AstraZeneca
  2. Bayer Healthcare Pharmaceuticals Inc.
  3. Bristol-Myers Squibb
  4. Clovis Oncology
  5. Genentech
  6. Novartis Oncology
  7. Otsuka America Pharmaceutical, Inc.
  8. Seattle Genetics, Inc.
  9. Takeda Oncology
  10. Actelion Pharmaceuticals US, Inc.
  11. Astellas
  12. Medivation, Inc.
  13. NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER

Ask authors/readers for more resources

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naive disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available